Kieron joined Clinigen in 2014 and is responsible for sourcing new opportunities for the business, which specializes in the consultancy, development, set up and implementation of Managed Access Programs on behalf of Biotech and Pharmaceutical companies. Prior to joining Clinigen, Kieron spent 15 years within the Pharmaceutical industry fulfilling a range of roles including Head of Cardiovascular Division at Servier Laboratories Ltd contributing to European and Global development plans. Within this time, Kieron has led a number of global pre-launch and launch activities for treatments addressing areas of high unmet medical need. Kieron now focusses his energies on working alongside Pharma and Biotech Companies to consider their strategy for Early Access, developing Global Programs and allowing patients to gain access to treatments that would otherwise be unavailable within their respective countries.
The rising cost of clinical development, coupled with the ethical obligation to ensure that patients exiting a clinical trial are able to remain on active treatment if necessary, has led some pharmaceutical and bio-pharmaceutical companies to review their trial protocols and consider alternative options. This session looks at some of the key considerations and how many companies are adopting different supply models.